Monday, Fennec Pharmaceuticals Inc. (FENC) announced the appointment of Jeffrey Hackman as chief executive officer and Board member, effective August 16, 2024.
Rosty Raykov, CEO since 2009, will continue to serve on the Board.
The company indicated that Hackman's appointment is intended to further the development of PEDMARK, the sole approved treatment in the U.S. designed to minimize the risk of cisplatin-induced ototoxicity in pediatric cancer patients.
Hackman brings over 30 years of experience in commercial leadership including 12 years in oncology, and has led more than 10 product launches and successfully brought products to market relevant to PEDMARK.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.